Indivior appoints Graham Hetherington as new Chairman of the Board of Directors

– UK, Slough –  Indivior PLC (LON: INDV) today announced the appointment of Graham Hetherington as Chair of the Board with immediate effect.

His appointment was approved by the Board and follows a succession process undertaken by the Nomination & Governance Committee and led by Lorna Parker, Chair of the Nomination & Governance Committee.

“We are pleased to announce that Graham Hetherington has been appointed Chair of the Board. Graham has a strong record of value creation including in specialty pharma. We look forward to his continued active participation and leveraging his deep strategic, operational and financial experience to achieve the Group’s strategic priorities.” said Daniel Tassé, Senior Independent Director.

About Graham Hetherington

Graham joined the Board as a Non-Executive Director in November 2019 and was appointed a member of the Audit and Remuneration Committees; he was appointed Chair of the Audit Committee in March 2020. Graham was previously Chair of the Audit Committee of BTG plc from 2016 and Senior Independent Director from 2017 until its acquisition by Boston Scientific Corporation in August 2019. He was previously CFO of Shire PLC, a global pharmaceutical company from 2008 until 2014, CFO of Bacardi and Company during 2007 and CFO of Allied Domecq plc from 1999 to 2005. He is a Fellow of the Chartered Institute of Management Accountants.

“Indivior is at an important stage of its development. I am honoured to be appointed Chair of the Board at this time. Indivior is a pioneer in its field and I look forward to working with the Board and leadership team to realize SUBLOCADE®’s (buprenorphine extended-release) full potential and more broadly its important Vision on behalf of all stakeholders.” commented Board Chair, Graham Hetherington.

About Indivior

Indivior is a global pharmaceutical company working to help change patients’ lives by developing medicines to treat addiction and serious mental illnesses. Our vision is that all patients around the world will have access to evidence-based treatment for the chronic conditions and co-occurring disorders of addiction. Indivior is dedicated to transforming addiction from a global human crisis to a recognized and treated chronic disease.

Building on its global portfolio of opioid dependence treatments, Indivior has a pipeline of product candidates designed to both expand on its heritage in this category and potentially address other chronic conditions and co-occurring disorders of addiction, including alcohol use disorder. Headquartered in the United States in Richmond, VA, Indivior employs more than 700 individuals globally and its portfolio of products is available in over 40 countries worldwide.

For more information:

- DisclaimerNews, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.